ML Strategies Adds Food & Drug Administration Senior Policy Advisor Aaron Josephson to Washington, D.C. Office
September 20, 2018
March 7, 2019 | Inside Health Policy
FDA Chair Bethany Hills and ML Strategies Senior Director Aaron Josephson are quoted in this article discussing the possibility of FDA Principal Deputy Commissioner Amy Abernethy filling in as acting FDA commissioner, or possibly even succeed FDA Commissioner Scott Gottlieb when the current commissioner leaves the agency in a month.
February 5, 2019 | MedPage Today
This article previews what may be said of health care in the 2019 State of the Union address. ML Strategies Vice President Rodney Whitlock, a veteran health care policy advisor in Washington, provides commentary in the piece.
December 28, 2018 | MedPage Today
Health care industry insiders notes that the actions that Congress decides to take on health care in 2019 will largely be for show. Veteran health care policy advisor Rodney Whitlock, a Vice President with ML Strategies, is among those sources providing commentary in the piece.
The final word on the ACA's fate is years away, legal analysts say. But it could get messy in the meantime
December 20, 2018 | FierceHealthcare
This feature article discusses the potential constitutionality of the Affordable Care Act (ACA) and how we could not know the final verdict for years to come. ML Strategies Vice President Rodney Whitlock, a veteran health care policy advisor in Washington, provides commentary in the piece.
December 19, 2018 | Washington Post
This Washington Post article discusses how a recent Texas judge’s decision finding the Affordable Care Act unconstitutional could impact Republicans in the House and Senate in the next Congress, as well as throughout the next election cycle. ML Strategies Vice President Rodney Whitlock, a veteran health care policy advisor, is quoted in the piece.
December 18, 2018 | Inside Health Policy
FDA Chair Bethany Hills and ML Strategies Senior Director Aaron Josephson are featured in this article discussing two recently-announced actions by the Food & Drug Administration (FDA) to encourage industry adoption of two accelerated review and development pathways for new devices. The FDA’s announcement centered upon a final guidance on the breakthrough devices pathway and recommendations for a new Safer Technologies Program (STeP).